Skip to Main Content

The biotech industry is worried that a proposed federal rule could further dampen overseas investment in U.S. startups, warning regulators that increased bureaucracy would stall the development of new medicines.

BIO, the industry’s largest trade group, is speaking out against a proposed rule that would expand the government’s power to review and block foreign investments in American companies.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!